Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesMyeloproliferative Diseases and Disorders, Poorly Differentiated NeoplasmsDRG 830-myeloproliferative-disorders-or-poorly-differentiated-neoplasms-with-other-procedures-without-cc-mcc
    Ask Trek AI about this page

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    DRG 830 addresses admissions for myeloproliferative disorders or poorly differentiated neoplasms with other procedures without Complication or Comorbidity or Major Complication or Comorbidity. Accurate DRG assignment affects Medicare inpatient reimbursement by aligning payment with expected resource use for hematology-oncology procedures and short inpatient stays.

    Customize your policy alerts

    Sign up for drg 830 policy alerts

    Get alerted when payer policies referencing 830 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 830 Overview

    DRG 830 covers hospital stays for patients with myeloproliferative disorders or poorly differentiated neoplasms who undergo other procedures and do not have a Complication or Comorbidity or a Major Complication or Comorbidity. This category groups admissions where procedure-related resources drive reimbursement, with clinical focus on hematologic malignancies and diagnostic or therapeutic interventions that are not categorized as major operations. It matters for Medicare payment because grouping determines the inpatient payment weight and influences resource allocation for hospitals treating these conditions.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute procedural and perioperative outcomes research: Trials and observational studies evaluating short-term outcomes, complications, and optimization of other invasive or procedural interventions performed in patients with myeloproliferative disorders or poorly differentiated neoplasms (for example central venous access placement, diagnostic biopsies, or non-hematologic surgeries) focus on the immediate inpatient episode. These studies enroll hospitalized adults with active myeloproliferative disease or aggressive/undifferentiated hematologic malignancies who undergo procedures without major complications (no CC/MCC), aiming to define predictors of bleeding, thrombosis, transfusion needs, and length of stay. Findings are highly relevant to hospitals and payers because they inform peri-procedural risk stratification, resource use, and protocols that can reduce complications and costs during the inpatient stay covered under this DRG.
    • Comparative effectiveness and supportive-care intervention studies: Research comparing strategies such as transfusion thresholds, anticoagulation management, growth factor use, or infection prophylaxis in medically managed inpatients with myeloproliferative disorders or poorly differentiated neoplasms examines which approaches yield better short-term clinical stability and fewer readmissions. These trials typically enroll heterogeneous adult patient populations with symptomatic cytopenias, thrombotic risk, or treatment-related complications but without major comorbid complications, and randomize or observe use of different supportive care pathways. Results guide clinicians and payers on cost-effective inpatient care bundles and guideline-concordant supportive therapies that can shorten stay and lower downstream utilization for this DRG cohort.
    • Post-discharge outcomes and transitions-of-care studies: Cohort studies and pragmatic trials investigating discharge planning, outpatient follow-up timing, and care coordination for patients hospitalized with myeloproliferative disorders or poorly differentiated neoplasms assess 30- to 90-day readmissions, emergency visits, and mortality. These studies enroll patients at discharge who had uncomplicated inpatient procedures or medical management (consistent with without CC/MCC) to evaluate interventions like early hematology follow-up, home health support, or structured education on symptom monitoring. Evidence from these studies is important to providers and payers because improving post-discharge management can reduce readmissions and total cost of care across the episode, directly impacting reimbursement and quality metrics associated with this DRG.

    Related Codes

    820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

    824-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-CC

    Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

    825-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    828-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    Showing 1–10 of 27

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.